Clinical Trials
2 trialsNCT05726175 2023-02-13
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
West China Hospital
Phase 2 Unknown
NCT05244993 2022-07-12
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown